We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sesen Bio

News List

Sesen Bio Enters Mfg. and Supply Partnership with Qilu Pharma contractpharma
December 10, 2020
Sesen Bio has entered into a commercial manufacturing and supply framework agreement—CMO Agreement—with the company's partner in China, Qilu Pharmaceutical.
Sesen Bio Reports Positive, Preliminary Data Update from Trial for Bladder Cancer americanpharmaceuticalreview
August 12, 2019
Sesen Bio reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicinium for the potential treatment of ...
Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium® americanpharmaceuticalreview
June 13, 2019
Sesen Bio has completed a successful Type B Pre-Biologics License Application (BLA) meeting regarding the approval path for Vicinium for the treatment of patients with high-risk, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder can